<DOC>
	<DOCNO>NCT02560337</DOCNO>
	<brief_summary>Many ovarian cancer patient offer different standard cytostatics gradually develop chemo-resistance . However , considerable fraction patient still good general health strong wish treatment . Cabazitaxel ( Jevtana® ) new taxane effect breast prostatic cancer . In tumor show effect patient refractory docetaxel . Therefore , could anticipate cabazitaxel may also effect chemo-resistant ovarian cancer . Tocotrienol fraction natural E-vitamin several biological effect , include effect malignant cell angiogenesis . The aim study investigate whether cabazitaxel tocotrienol could reasonable treatment option patient chemo-resistant refractory ovarian cancer regard effect toxicity . In case progression cabazitaxel option cross tocotrienol vice versa .</brief_summary>
	<brief_title>Cabazitaxel vs. Tocotrienol Patients With Recurrent Ovarian Cancer After Failure Standard Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<criteria>Histologically confirm epithelial , primary fallopian primary peritoneal cancer . Platinum resistant ovarian cancer least two previous cytostatic regimen platinumrefractory disease define progression receive last line platinum base therapy within 4 week last platinum dose Progression previous treatment . Measurable disease RECIST 1.1 evaluable GCIG CA125 criterion Age ≥ 18 year . Performance status 02 . Adequate bone marrow function , liver function , renal function ( within 7 day prior inclusion ) : Neutrophils ( ANC ) ≥ 1.5 * 10^9/l Platelet count ≥ 100 * 10^9/l Hemoglobin ≥ 9.0 g/dL ≥ 5.6 mmol/l Serum bilirubin ≤ 1.0 * ULN Serum transaminase ≤ 2.5 * ULN Serum creatinine ≤ 1.5 ULN ( creatinine 1.5 x ULN measure GFR must least 50 ml / min ) Remaining life expectancy least 3 month Written inform consent History severe hypersensitivity reaction ( ≥grade 3 ) taxol . History severe hypersensitivity reaction ( ≥grade 3 ) polysorbate 80 contain drug . Allergy active substance auxiliary agent . Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4/5 ( 2week washout period necessary patient already treatment ) Neuropathy grade ≥ 2 . Pregnant breastfeeding patient . For fertile woman negative pregnancy test screen mandatory . Fertile patient willing use effective method contraception treatment 6 month end treatment . Other malignant disease within 5 year prior inclusion study , except basal cell squamous cell carcinoma skin cervical carcinomainsitu . Other experimental therapy participation another clinical trial within 28 day prior treatment initiation . History chronic medical psychiatric condition laboratory abnormality medically control opinion investigator may increase risk associated study drug administration . ( e.g . diabetes , cardiac disease , hypertension , renal , thyroid liver disease ) . Vaccination yellow fever vaccine live attenuated vaccine treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Relapse</keyword>
	<keyword>Recurrence</keyword>
	<keyword>Chemotherapy resistance</keyword>
</DOC>